Sponsor:
Anebulo Pharmaceuticals
Code:
NCT06017622
Conditions
Acute Cannabis-induced CNS Depression
Eligibility Criteria
Sex: All
Age: 0+
Healthy Volunteers: Not accepted
Brief summary:
Conditions
Acute Cannabis-induced CNS Depression
Study ID
NCT06017622
Start date
Jun 1, 2023
Status verified date
Feb, 2026
Completion date
Dec 30, 2026
Anticipated
Primary completion date
Dec 30, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 0+
Healthy Volunteers: Not accepted
Enrollment
36 participants
Anticipated
Arms
All subjects
Primary outcome measure
Central contacts
Locations
University of Massachusetts Memorial Children's Medical Center
Recruiting
Worcester, Massachusetts, United States, 01605
Contacts
Principal Investigator:
Zachary W. Binder, MD
Cincinnati Children's Hospital
Recruiting
Cincinnati, Ohio, United States, 45229
Contacts
Principal Investigator:
Melinda Mahabee-Gittens, MD, PhD
Oregon Health and Sciences University
Recruiting
Portland, Oregon, United States, 97329
Contacts
Principal Investigator:
Robert G. Hendrickson, MD, FACMT
Sponsor
Anebulo Pharmaceuticals
Last update posted
Jul 30, 2026
Last verified
Feb, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Anebulo Pharmaceuticals on 2026-07-30.